Plain-English translation of NCT06158412 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing all-trans retinoic acid (ATRA) combined with a three-drug regimen called KPD in patients with multiple myeloma that has relapsed (come back) or become refractory (stopped responding to prior treatment). The study will measure how well this medication combination works and what side effects patients experience. Researchers hope this new approach may help people whose myeloma is no longer controlled by standard treatments.
Multiple myeloma is a cancer of plasma cells in the bone marrow, and many patients eventually develop disease that either returns after treatment or stops responding to their current medications. This trial exists because doctors need better options for these patients, and early research suggests this medication combination may offer hope.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication combination (all-trans retinoic acid plus KPD regimen) over multiple treatment cycles. You would attend regular clinic visits for examinations, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The study will follow your response to treatment, overall survival, and how long the disease remains under control.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment target
~25 participants
Started
November 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhijuan Lin, PhD
The First Aiffiliated hosptical of xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.